Payment of an overdue $120m Astrazeneca milestone, plus two other obligations, has been met through a loan facility with undisclosed terms.
May looks to be a fairly quiet month for US drug approvals, though Novartis's gene therapy should make headlines.
Intra-Cellular looks to shore up lumateperone, while Myovant wants to take on Abbvie on its own turf.
Transvaginal mesh implants are banned in the US, but remain a possibility in Europe.
Roche awaits a high-risk, high-reward readout in autism, while for Ocular Therapeutix placebo ought to be easier to beat than active control.
Business development decisions have started the clock on a financial time bomb set to go off within the next three months.
Six months after floating, Urovant is gearing up to release pivotal data on its most advanced overactive bladder project.
The failure of one of Allergan’s key pipeline projects puts the group’s chief executive under even more pressure.
After two other liver disease projects fade into the background Ionis delays the antisense asset AKCEA-ANGPTL3-LRx by a year.